Home › Compare › AMPE vs QYLD

AMPE vs QYLD: Dividend Comparison 2026

AMPE yields 1311.05% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMPE wins by $207537754.82M in total portfolio value
10 years
AMPE
AMPE
● Live price
1311.05%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207537754.85M
Annual income
$180,460,634,612,456.80
Full AMPE calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — AMPE vs QYLD

📍 AMPE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMPEQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMPE + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AMPE pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMPE
Annual income on $10K today (after 15% tax)
$111,438.87/yr
After 10yr DRIP, annual income (after tax)
$153,391,539,420,588.28/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, AMPE beats the other by $153,391,539,415,777.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMPE + QYLD for your $10,000?

AMPE: 50%QYLD: 50%
100% QYLD50/50100% AMPE
Portfolio after 10yr
$103768877.44M
Annual income
$90,230,317,309,058.06/yr
Blended yield
86.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMPE right now

AMPE
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-63.7
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMPE buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMPEQYLD
Forward yield1311.05% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$207537754.85M ✓$25.4K
Annual income after 10y$180,460,634,612,456.80 ✓$5,659.31
Total dividends collected$205538221.53M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AMPE vs QYLD ($10,000, DRIP)

YearAMPE PortfolioAMPE Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$141,805$131,104.56$10,352$1,192.36+$131.5K → AMPE
2$1,889,228$1,737,497.51$10,830$1,347.57+$1.88M → AMPE
3$23,655,368$21,633,893.61$11,460$1,539.07+$23.64M → AMPE
4$278,471,869$253,160,624.79$12,275$1,777.84+$278.46M → AMPE
5$3,083,213,738$2,785,248,838.88$13,323$2,078.95+$3083.20M → AMPE
6$32,119,606,169$28,820,567,469.38$14,667$2,463.34+$32119.59M → AMPE
7$314,966,468,315$280,598,489,713.88$16,396$2,960.57+$314966.45M → AMPE
8$2,908,568,193,145$2,571,554,072,047.85$18,631$3,612.97+$2908568.17M → AMPE
9$25,305,719,846,817$22,193,551,880,152.03$21,548$4,482.15+$25305719.83M → AMPE
10$207,537,754,848,551$180,460,634,612,456.80$25,398$5,659.31+$207537754.82M → AMPE

AMPE vs QYLD: Complete Analysis 2026

AMPE — Stock

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Full AMPE Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this AMPE vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMPE vs SCHDAMPE vs JEPIAMPE vs OAMPE vs KOAMPE vs MAINAMPE vs XYLDAMPE vs JEPQAMPE vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.